维迪西妥单抗联合程序性死亡受体1抑制剂用于膀胱癌新辅助治疗的疗效与不良反应探索

打开文本图片集

ABSTRACT：ObjectiveTo explore the efficacy andadverse events of antibody-drug conjugate（ADC）combined with PD-1 inhibitorsinneoadjuvant therapy for muscle-invasive bladdercancer.MethodsAretrospectivestudy included 22 patients with bladder cancer who received neoadjuvant therapy with ADC combined with PD-1 inhibitors and gemcitabine + cisplatin （GC）regimencombined with PD-1inhibitors in the Departmentof Urology，Cancer Hospital，Chinese Academyof Medical Sciences from Nov.2O2OtoJan.2025.The patients were divided into the vedotinumabcombined with toripalimab groupand the GC combined with toripalimab group.The clinical complete response rate（cCR）of the two groups of patients was compared and analyzed，and the adverse events（AEs）that ocurred during the medication period were evaluated simultaneously.ResultsTheCR in thevedotinmab combinedwith toripalimab groupwas higher than that in the GC combined with toripalimab group （54.5% vs. 27.3% ），but the difference was not statistically significant （ P=0.387： .Inthe vedotinumab combined with toripalimab group，one patient （9.1% ）developed grade 3-4 AEs，presenting with peripheral sensory nerve function decline， nausea，loss of appetite and fatigue. Two patients （ 18.2% ）in the GC combined with toripalimab group developed grade 3-4 AEs，presenting with leukopenia and nausea. Conclusion In neoadjuvant therapy for bladdercancer，ADC（vedotinumab）combined with PD-1inhibitors（toripalimab）has beter clinicalcompleteremissonand adverse events compared with the traditional GC combined with PD-1 inhibitors regimen.

KEY WORDS：neoadjuvant chemotherapy；programmed cell death1 inhibitors；muscle-invasive bladdercancer; vedotinumab; toripalimab;gemcitabine;cisplatin

中图分类号：R737.14 文献标志码：A DOI：10.3969/j.issn.1009-8291.2025.10.002

膀胱癌（bladdercancer，BCa）作为泌尿系统常见的恶性肿瘤之一，在全球范围内呈现显著的疾病负担。（剩余5973字）